Emergent BioSolutions director trades and gets awards

Emergent BioSolutions director Keith Katkin reported both a sale and new equity awards.

Rhea-AI Filing Summary

Emergent BioSolutions director Keith Katkin reported both a sale and new equity awards. He sold 15,481 shares of common stock at a weighted average price of $8.28 per share under a Rule 10b5-1 trading plan to satisfy tax obligations from RSUs that vested on April 29, 2026. On the same date, he received an annual grant of 25,344 restricted stock units for board and committee service, which will vest the day before the one-year anniversary of the grant if he remains on the board. He also received 11,296 stock options with a $7.99 exercise price, expiring April 30, 2033, and reported holding 111,775 shares directly after these transactions.

Insider Trade Summary 10b5-1

Net Seller: 15,481 shares

Net Sell 3 txns

Insider Katkin Keith

Role Director

Sold 15,481 shs ($128K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	11,296	$0.00	$0.00
Grant/Award	Common Stock	25,344	$0.00	$0.00
Sale	Common Stock	15,481	$8.28	$128K

Holdings After Transaction: Stock Options (Right to Buy) — 11,296 contracts (Direct); Common Stock — 96,294 shares (Direct)

Footnotes (5)

1. F1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
2. F2. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
3. F3. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
4. F4. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
5. F5. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

Key Figures

Shares sold: 15,481 shares Sale price: $8.28 per share RSU grant: 25,344 shares +4 more

7 metrics

Shares sold 15,481 shares Open-market sale on April 30, 2026

Sale price $8.28 per share Weighted average sale price

RSU grant 25,344 shares Annual restricted stock unit award for director service

Option grant size 11,296 options Stock options granted for board and committee service

Option exercise price $7.99 per share Exercise price for new stock options

Option expiration April 30, 2033 Expiration date of granted stock options

Shares held after transactions 111,775 shares Direct common stock holdings after reported Form 4

Key Terms

restricted stock units ("RSUs"), Rule 10b5-1 trading plan, Stock Options (Right to Buy), Black-Scholes value

4 terms

restricted stock units ("RSUs") financial

"Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Rule 10b5-1 trading plan regulatory

"Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Options (Right to Buy) financial

"security_title": "Stock Options (Right to Buy)""

Black-Scholes value financial

"dividing by the Black-Scholes value of a single option calculated as of the date of the grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Emergent BioSolutions (EBS) director Keith Katkin report?

Katkin reported selling 15,481 Emergent BioSolutions shares and receiving new equity awards. The sale was an open‑market transaction, while he also received 25,344 restricted stock units and 11,296 stock options as part of his annual non‑employee director compensation package.

At what price did Keith Katkin sell Emergent BioSolutions (EBS) shares?

Katkin’s sale used a weighted average price of $8.28 per share. The filing notes multiple trades executed between $8.23 and $8.36, and he undertook to provide detailed trade breakdowns upon request to investors or regulators.

Why did Keith Katkin sell Emergent BioSolutions (EBS) shares under a Rule 10b5-1 plan?

The shares were sold under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 10, 2025. Proceeds were used to satisfy tax obligations related to restricted stock units that vested on April 29, 2026, making the sale part of tax management rather than a discretionary trade.

What new equity awards did Keith Katkin receive from Emergent BioSolutions (EBS)?

Katkin received 25,344 restricted stock units and 11,296 stock options for board and committee service. Each RSU converts into one common share at vesting, and each option allows purchase of one share at the fixed exercise price specified in the grant.

When do Keith Katkin’s new Emergent BioSolutions (EBS) RSUs and options vest?

Both the RSUs and stock options vest on the day before the one‑year anniversary of the grant date. Vesting is conditioned on Katkin continuing to serve on Emergent BioSolutions’ board of directors through that vesting date, according to the filing.

How many Emergent BioSolutions (EBS) shares does Keith Katkin hold after these transactions?

After the reported sale and RSU grant, Katkin directly holds 111,775 shares of Emergent BioSolutions common stock. This updated holding reflects both the disposition of 15,481 shares and the acquisition of 25,344 additional shares through restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 05:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Katkin Keith

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		A		25,344(1)	A	$0	111,775	D
Common Stock	04/30/2026	04/30/2026	S		15,481(2)	D	$8.28(3)	96,294	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$7.99	04/30/2026		A		11,296		(4)	04/30/2033	Common Stock	11,296(5)	$0	11,296	D

Explanation of Responses:

1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

2. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

3. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

4. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

5. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)